Medigene Announces Results from Investigator Initiated Trial of EndoTAG®-1 to be Published for ASCO 2013

Medigene AG / Medigene Announces Results from Investigator Initiated Trial of EndoTAG®-1 to be Published for ASCO 2013 . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Martinsried/Munich, April 11, 2013. Medigene AG (Frankfurt, Prime Standard; MDG) announced today that the results from the Phase 2 investigator initiated trial (IIT) of EndoTAG^®-1 in HER2-negative breast cancer will be published for the upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO). The abstract (#114428), entitled "Feasibility study of cationic liposome-encapsulated paclitaxel in combination with paclitaxel followed by FEC as induction therapy in HER2-negative breast cancer" was chosen for inclusion online in the ASCO 2013 Annual Meeting Proceedings, a Journal of Clinical Oncology supplement, and will be released at www.asco.org on May 15, 2013.

The investigator initiated trial with EndoTAG^®-1 was conducted by Prof. Dr. Ahmad Awada, Head of the Medical Oncology Clinic at the Institut Jules Bordet in Brussels, Belgium, and principal investigator in the previously conducted EndoTAG^®-1 phase II trial in locally relapsed and/or metastatic advanced Triple Negative Breast Cancer (TNBC). The aim of the exploratory open-label Phase 2 IIT was to evaluate the efficacy and safety of neoadjuvant EndoTAG^®-1 in combination with paclitaxel in patients with HER2-negative breast cancer.

About EndoTAG^®-1: EndoTAG^®-1 is a novel composition of the established cytostatic drug paclitaxel combined with neutral and positive lipids. The positively charged lipids imply that EndoTAG^®-1 interacts with newly developed, negatively charged endothelial cells, which are primarily required for the growth of tumor blood vessels. The EndoTAG^®-1 paclitaxel component attacks the endothelial cells as they divide, thus targeting the blood supply to tumors without affecting the supply to healthy tissue. By doing this, EndoTAG^®-1 is expected to prevent the formation of new tumor blood vessels and to inhibit tumor growth. Medigene has successfully completed two clinical phase II trials of EndoTAG^®-1 in the indications pancreatic cancer and triple-negative breast cancer (TNBC).

Medigene AG (Frankfurt: MDG, prime standard) is a publicly listed biotechnology company headquartered in Martinsried/Munich, Germany. Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases. Medigene is the first German biotech company to have revenues from a marketed product (Veregen^®), which is distributed by partner companies. Medigene has two drug candidates in clinical trials, EndoTAG^®-1 and RhuDex^®, and is developing an innovative vaccine technology. For more information, please visit www.medigene.com.

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene^® and Veregen^® are registered trademarks of Medigene AG. Polyphenon E^® is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or licensed in select locations only.

Contact

Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: [e-mail]

To unsubscribe from the press release distribution list, please go to www.medigene.com/unsubscribe.

Press release as PDF

---

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Medigene AG via Thomson Reuters ONE

HUG#1692200